Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Pegargiminase

Recombinant protein · Acts on arginine · developed by Polaris Group

Phase 2/3 Most advanced trial
1 Registered trials

What is Pegargiminase?

Pegargiminase is arginine deiminase conjugated to polyethylene glycol that degrades the amino acid arginine to citrulline. It is studied in glioblastoma, targeting arginine-dependent cancer cells while sparing normal cells that can synthesize arginine endogenously.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
ADI-PEG 20
Drug type
Recombinant protein
Targets
arginine
Mechanism
Acts on arginine
Pathways
cellular proliferation inhibition
Therapy area
Oncology
Developer
Polaris Group
In trials of
BHVN
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII
0B7PYQ9YRT

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03970447 Phase 2/3 Glioblastoma Recruiting BHVN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Glioblastoma

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.